Close Menu

NEW YORK (GenomeWeb) – UK biotech startup Methuselah Health plans to use analysis of protein post-translational modifications to develop drugs and diagnostics for age-related diseases.

The company, which launched in 2015 but has only recently begun publicizing its work, believes protein PTMs can provide insights into protein damage that can be used to address common late-onset conditions like atherosclerosis, Alzheimer's, and auto-immune disorders, said David Grainger, Methuselah's executive chairman and CEO.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.